Barrett Katz - Jan 9, 2023 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Chief Medical Officer
Signature
/s/ Lara Meisner, Attorney-in-Fact for Barrett Katz
Stock symbol
VRDN
Transactions as of
Jan 9, 2023
Transactions value $
-$707,672
Form type
4
Date filed
1/11/2023, 06:09 PM
Previous filing
Feb 3, 2022
Next filing
Jan 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRDN Common Stock Options Exercise $291K +12.6K $23.03 12.6K Jan 9, 2023 Direct
transaction VRDN Common Stock Sale -$417K -12.6K -100% $33.04 0 Jan 9, 2023 Direct F1
transaction VRDN Common Stock Options Exercise $1.09M +47.4K $23.03 47.4K Jan 10, 2023 Direct
transaction VRDN Common Stock Sale -$1.67M -47.4K -100% $35.30 0 Jan 10, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -12.6K -3.55% $0.00 343K Jan 9, 2023 Common Stock 12.6K $23.03 Direct F3
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -47.4K -13.8% $0.00 296K Jan 10, 2023 Common Stock 47.4K $23.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $33.00 to $33.135. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $33.76 to $35.934. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The option vested 25% on January 18, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.